Platelet and Hemoglobin Monitoring with Subcutaneous Heparin Prophylaxis
Obtain a baseline platelet count before initiating heparin (or within the first 4 days), then monitor platelets based on HIT risk stratification—no routine monitoring is needed for low-risk patients, but intermediate and high-risk patients require serial platelet counts from days 4-14. 1, 2
Risk Stratification for Platelet Monitoring
The monitoring strategy depends entirely on your patient's HIT risk category:
Low-Risk Patients (<0.1% HIT risk):
- Medical patients receiving LMWH prophylaxis
- Obstetric patients receiving prophylactic LMWH
- Patients receiving fondaparinux
- No routine platelet monitoring required 1, 2
- However, check platelets immediately if any unexpected clinical event occurs (new thrombosis, skin necrosis, unusual injection site reactions) 2
Intermediate-Risk Patients (0.1-1.0% HIT risk):
- Medical patients receiving UFH
- Obstetric patients receiving UFH
- Patients receiving LMWH after major surgery or major trauma
- Monitor platelets 1-2 times per week from day 4 to day 14 2
- Continue weekly monitoring for one month if heparin continues beyond 14 days 2
High-Risk Patients (>1.0% HIT risk):
- Surgical patients receiving postoperative UFH
- Trauma patients receiving UFH
- Patients on ECMO requiring IV UFH
- Monitor platelets 2-3 times per week (or every 48 hours) from day 4 to day 14 1, 2
- Continue weekly monitoring for one month if heparin continues 2
Critical Timing Considerations
If the patient received heparin within the past 30-100 days, start monitoring immediately on day 0 (the day heparin is initiated) because pre-existing antibodies can cause rapid-onset HIT 1, 2. This is a common pitfall—don't wait until day 4 in previously exposed patients.
The monitoring window of days 4-14 captures the vast majority of HIT cases, though rare cases occur up to 3 weeks with LMWH 2. After one month, HIT risk becomes negligible and monitoring can stop 2.
What Constitutes Significant Thrombocytopenia
Suspect HIT when:
- Platelet count drops ≥50% from baseline (even if still >150,000/μL)
- Platelet count falls below 100,000/μL
- This occurs between days 5-14 of heparin therapy (or earlier if recent heparin exposure) 2
Use the baseline platelet count obtained before starting heparin as your reference point 2. The FDA label reinforces this: "Periodic platelet counts, hematocrits and tests for occult blood in stool are recommended during the entire course of heparin therapy, regardless of the route of administration" 3.
Hemoglobin Monitoring
Check hemoglobin/hematocrit periodically throughout heparin therapy to detect occult bleeding 3. The FDA label specifically recommends this alongside platelet monitoring and stool guaiac testing, though no specific frequency is mandated. A practical approach is to check CBC (which includes both platelets and hemoglobin) according to the platelet monitoring schedule above, plus any time bleeding is suspected clinically.
When HIT is Suspected
If platelets drop significantly:
- Calculate the 4T score immediately to assess pretest probability 1, 2
- Stop all heparin (including flushes) if intermediate or high probability
- Send HIT antibody testing (immunoassay first, then functional assay if positive) 1
- Start alternative anticoagulation (lepirudin, danaparoid, argatroban, fondaparinux) at therapeutic doses unless contraindicated 1
Common Pitfalls to Avoid
- Don't assume low-dose prophylactic heparin is safe from HIT—while one older study suggested no monitoring needed 4, current guidelines clearly stratify by patient population and heparin type, not just dose
- Don't forget to check baseline platelets—you cannot identify a 50% drop without knowing the starting value 2
- Don't continue monitoring beyond 1 month—the risk becomes negligible 2
- Don't ignore thrombocytopenia just because platelets remain >100,000/μL—a 50% drop is significant regardless of absolute value 2
The 2020 French guidelines 2 provide the most granular monitoring frequencies and align closely with the 2018 ASH guidelines 1, representing the current standard of care for platelet monitoring during heparin prophylaxis.